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SUMMARY Oral lichen planus (OLP) is an immunologically T cell-mediated 
disease caused by an unknown stimulus. Despite intensive investigation its 
pathogenesis still remains unknown. A few possible associations between 
OLP and certain diseases such as thyroid and malignant diseases as well as 
specific medication intake have been proposed in the literature with incon-
sistent findings.
We aimed to investigate the profile of 163 Australian and 163 Croatian OLP 
patients with special regard to their systemic diseases, medication intake 
(with special regard to the drugs that metabolize through Cytochrome 
P450), OLP type and localization, as well as involvement of other body sur-
faces with lichen. We did not find any statistical significance with regard to 
the OLP presence and thyroid and malignant diseases. As expected, the 
reticular type of OLP was most prevalent, as well as involvement of the 
both buccal mucosas. There was no significant association with other oral 
diseases such as labial herpes. Simultaneous involvement of other body 
surfaces in patients with OLP does not seem to be prevalent. None of the 
medical conditions which were investigated had significant correlation with 
OLP neither in Australian nor in Croatian patients with OLP. Furthermore, 
the use of drugs which metabolize through Cytochrome P450 (CYP450) was 
not significantly correlated with OLP in either studied population. Therefore, 
we conclude that patients with OLP are not to be routinely screened for any 
systemic conditions.
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INTRODUCTION
Oral lichen planus (OLP) is probably the second 
most common oral mucosal disease, affecting 0.5-
2% of the general population (1). OLP is a T cell-me-
diated disease caused by a still unknown antigen. 
Certain diseases have been associated with OLP in 
the past, such as diabetes, hypertension, hepatitis C 
infection (HCV), thyroid disease, and malignant dis-
eases. A connection between OLP and thyroid dis-
ease has been proposed, although data are scarce 
and limited to Siponen et al. (2) and Compilato et al. 
(3). The idea of paraneoplastic lichen planus mainly 
relies on the 12 case reports in patients with simul-
taneous OLP and malignant lesions (4,5). However, 
it is very unlikely that OLP patients should be rou-
tinely screened for malignant diseases in other parts 
of the body. 
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Male 45 (27.6%) 40 (25.0%) 0.383 1 0.59
Female 118 (72.4%) 120 (75.0%)
Type of OLP
Reticular 117 (71.8%) 97 (60.6%) 4.493 1 0.03
Erosive 46 (28.2%) 63 (39.4%)
Recently, Kragelund et al. (6) reported increased 
prevalence of medication intake which metabolize 
through Cytochrome P450 (CYP450). 
New entities of OLP together with vulval/vaginal 
and penile involvement are being noted in the litera-
ture, and the true prevalence of this simultaneous in-
volvement is yet to be established (7,8). 
Therefore, the aim of this study was to assess the 
medical and oral profile of Australian and Croatian 
OLP patients, as well as OLP characteristics, with spe-
cial regard to all known parameters which might con-
tribute to development of OLP. 
Furthermore, the rationale for comparing Austra-
lian and Croatian population was the fact that OLP 
presentation and correlation with systemic diseases 
varies between different geographic parts of the 
world.
MATERIALS AND METHODS
Australian patients with OLP were recruited from 
a private oral medicine practice in Brisbane, Austra-
lia. There were 163 patients with OLP between 34 
and 92 years of age (mean 59.95 yrs). There were 118 
women (72.4%) and 45 men (27.6%). In 63 patients, 
OLP was confirmed histologically when in doubt, in 
others OLP was diagnosed by one experienced oral 
medicine specialist. Medical history and use of medi-
cation was obtained from each participant. Medica-
tions were then analyzed regarding the mechanism 
of metabolizing through CYP450 according to the 
MIMS 2005. 
Croatian patients with OLP were recruited from 
the Department of Oral Medicine in Zagreb, Croatia. 
There were 163 patients with OLP whose age range 
was 22-85 yrs, mean 56 yrs. There were 120 females 
(75%) and 40 males (25%). Patients from the both 
groups were Caucasian.
Every patient underwent clinical examination 
with special regard to type and localization of OLP as 
well as registration of other oral diseases. 
We also investigated involvement of other body 
parts with lichen planus as reported by patients 
themselves and when indicated confirmed by other 
specialists. The Statistical program used was Statis-
tica 7 (Statsoft, Tulsa, USA, 2005). Data was analyzed 
by means of descriptive statistics and Pearson Chi-
square. 
Table 1. Demographic data on patients with oral lichen planus (OLP)
Presentation
Unilateral 17 (10.4%) 10 (6.3%) 1.841 1 0.17
Bilateral 146 (89..6%) 150 (93.7%)
Localization
Buccal 58 (35.8%) 66 (41.2%) 15.409* 8 0.052
Tongue 7 (4.3%) 2 (1.2%)
Gingiva 21 (12.9%) 8 (5%)
Lips  2 (1.2%) 0 (0%)
Buccal+gingiva 13 (8%) 29 (18.2%)
Buccal+palatal 4 (2.6%) 6 (3.7%)
Buccal+tongue 45 (27.9%) 41 (25.7%)
Buccal+gingiva+tongue 9 (5.5%) 3 (1.9%)






Table 2. Oral licen planus (OLP) presentation and localization in Australian patients and Croatian patients
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yes 58 (35.6%) 66 (41.2%) 1.096 1 0.29
no 105 (64.4%) 94 (58.8%)
Asthma
yes 25 (15.3%) 9 (5.6%) 8.087 1 0.004
no 138 (84.7%) 151 (94.4%)
Carcinoma
yes 29 (17.8%) 6 (3.7%) 16.48 1 0.001
no 134 (82.2%) 154 (96.3%)
Allergies
yes 47 (28.8%) 7 (4.4%) 34.69 1 0.0001
no 116 (71.2%) 153 (95.6%)
Thyroid diseses
yes 15 (9.2%) 22 (13.7%) 1.64 1 0.199
no 148 (90.8%) 138 (86.3%)
Diabetes
yes 22 (13.5%) 14 (8.8%) 1.837 1 0.175
no 141 (86.5%) 146 (91.2%)
Hepatitis C
yes 4 (2.5%) 5 (3.1%) 0.001* 1 0.974
no 159 (97.%) 155 (96.2%)
*=Yates correction
RESULTS
Table 1 presents data regarding the gender of OLP 
patients in both groups, as well as the type of OLP le-
sions. There is a significant difference between Aus-
tralians and Croatians in the prevalence of OLP types, 
erosive OLP being more prevalent in the Croatian 
sample.
Table 2 shows OLP presentation and localization 
in Australian and Croatian patients. No significant dif-
ferences between the two groups regarding OLP pre-
sentation and localizations could be found. 
Table 3 presents systemic diseases found in both 
groups. No significant correlations regarding system-
ic diseases and OLP in either group could be found. 
However, there were significant differences between 
Australian and Croatian OLP patients regarding the 
prevalence of asthma, carcinoma, and allergies, i.e. 
Australians had increased incidence of these diseases 
in comparison with the Croatians.
Table 4 presents medications that metabolize 
through CYP 450 and those that do not in both 
groups of patients. Both groups of patients take more 
medications that do not metabolize through CYP450. 
However, Australian OLP patients take more non-ste-
roidal anti-inflammatory drugs (NSAIDs), antacids and 
hormones that do metabolize through CYP450, when 
compared to Croatian OLP patients. A standardized 
list of drugs and diseases was made for each patient.
Table 5 shows involvement of other body surfac-
es with OLP in both studied groups. There were no 
significant differences regarding the involvement of 
other body surfaces between Australian and Croa-
tian OLP patients. Additionally, involvement of other 




OLP has been described as a part of the paraneo-
plastic syndrome in some patients suffering from 
malignant neoplasms such as thymoma, lymphoma, 
histiocytoma, sarcoma, and breast carcinoma (4). Ma-
lignant disease was found in 29 Australian patients 
with OLP (17.8%) and in 6 Croatian patients with OLP 
(3.7%). 
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Table 3. Systemic diseases in Australian and Croatian patients with oral lichen planus
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In some countries, an association between hepa-
titis C virus infection and OLP was reported, although 
these were probably accidental findings (9-11). How-
ever, in this study no association with hepatitis A, B, C 
virus infection could be established, as only 4 Australian 
patients with OLP out of 163 had a history of hepatitis 
(2.5%), and 5 out 163 (3.1%) Croatian patients with OLP. 
No significant association between OLP and asth-
ma, hypertension, diabetes, and allergies could be 
found in either studied population. However, there 
was a significant difference between Australian and 
Croatian patients with OLP regarding the prevalence 
of asthma, carcinoma, and allergies, i.e. Australians 
with OLP had increased prevalence of these diseases 
in comparison with Croatian patients.
It was also reported in the literature that patients 
with OLP have a more prevalent history of thyroid 
disease (2). However, only 15 Australian patients with 
OLP (9.2%) and 22 Croatian patients with OLP (13.7%) 
had thyroid disease. Therefore, we could not confirm 
the findings of the abovementioned authors, which is 
in accordance with Compilato et al. (3).
MEDICATIONS
Cardiovascular
yes 59 36.2%) 66 (41.3%) 0.869 1 0.351
no 104 (63.8%) 94 (58.7%)
m-CYP450 39 (23.9%) 26 (16.2%) 2.96 1 0.085
nm-CYP450 124 (76.1%) 134 (83.8%)
NSAID
yes 31 (19 %) 18 (11.3%) 3.786 1 0.052
no 132 (81%) 142 (88.7%)
m-CYP450 30 (18.4%) 15 (9.4%) 5.491 1 0.019
nm-CYP450 133 (81.6%) 145 (90.6%)
Thyroid
yes 13 (8%) 19 (11.9%) 1.376 1 0.241
no 150 (92%) 141 (88.1%)
Reduce fat
yes 27 (16.6%) 15 (9.4%) 3.689 1 0.055
no 136 (83.4%) 145 (90.6%)
m-CYP450 24 (14.7%) 14 (8.8%) 2.776 1 0.096
nm-CYP450 139 (85.3%) 146 (91.2%)
Antacid
yes 25 (15.3%) 15 (9.4%) 2.646 1 0.104
no 138 (84.7%) 145 (90.6%)
m-CYP450 24 (14.8%) 7 (4.4%) 9.967 1 0.001
nm-CYP450 139 (85.2%) 153 (95.6%)
Psychiatric
yes 26 (16%) 21 (13.1%) 0.519 1 0.471
no 137 (84%) 139 (86.9%)
m-CYP450 24 (14.7%) 13 (8.1%) 3.99 1 0.046
nm-CYP450 139 (85.3%) 147 (91.9%)
Hormones
yes 22 (13.5%) 1 (0.6%) 18.328* 1 0.001
no 141 (86.5%) 159 (99.4%)
m-CYP450 19 (17.8%) 0 (0%) 17.766* 1 0.001
nm-CYP450 144 (88.3%) 160 (100%)
*=Yates correction, m-CYP450=metabolised through cytochrome P450, nm-CYP450= non metabolised 
through cytochrome P450
Table 4. The use of drugs that do and do not metabolize in Australian and Croatian patients with oral lichen 
planus 
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Oral mucosa 145 (89%) 142 (88.8%) 1.129 2 0.567
Oral mucosa+skin 15 (9.2%) 17 (10.6%)
Oral+other mucosas 3 (1.8%) 1 (0.6%)
Medication intake
Kragelund et al. (6) suggested that 91% of their 
patients with OLP were taking drugs which have in-
hibitory effect on CYPs. However, we were unable 
to confirm this finding, as 23.9% Australian patients 
and 16.2% of Croatian patients with OLP were tak-
ing cardiovascular agents that metabolize through 
CYP 450. Therefore, most cardiovascular agents that 
both groups were taking do not metabolize through 
CYP450. Additionally, there were no significant differ-
ences between Australians and Croatians regarding 
the number of cardiovascular agents taken.
However, 18.4% Australians with OLP were taking 
non-steroidal anti-inflammatory drugs which metab-
olize through CYP450 when compared to 9.4% Croa-
tians, which is a significant difference.
Furthermore, Australians with OLP took signifi-
cantly more antacids and hormones that metabolize 
through CYP450 when compared with the Croatians. 
Australians were taking more hormones in general 
when compared with the Croatians.
We could not confirm that use of drugs which me-
tabolize through CYP450 is associated with OLP, as 
the majority of the Australian and Croatian patients 
were taking meds that do not metabolize through 
CYP450.
Lower rate of erosive OLP in Australian patients 
could not be correlated with NSAID use, as out of the 35 
Australian patients with erosive OLP only 9 took NSAID.
Additional data regarding Australian OLP patients:
It is interesting to note that two patients had a his-
tory of reemergence of OLP – in one after cessation 
and return of OLP with repeated use of non-steroi-
dal anti-inflammatory drugs (NSAID) (Vioxx®, NSAID, 
COX-2 inhibitors). Oral lichen planus started with 
hormone replacement therapy in one of our patients, 
with NSAID (Celebrex®, NSAID, COX-2 inhibitor) in 
another one, with asthma medication in a third one. 
In one patient, OLP resolved after Vioxx® cessation 
(NSAID, COX-2 inhibitor), in another after Celebrex® 
(NSAID, COX-2 inhibitor) cessation, after Metoprolol® 
(Betaloc®, beta-adrenergic blocking agent; meto-
prolol tartarate) cessation in a third, in a fourth after 
treatment of hemochromatosis, and in one it resolved 
spontaneously.
Gender, type and localization of OLP
In the Australian group, there were 118 women 
(72.4%) and 45 men (27.6%), and 120 (75%) women 
and 40 (25%) men in the Croatian group, which is 
consistent with other studies (12).
The most common presentation was reticular OLP 
(71.8%) in the Australian group as well as in the Croa-
tian group (60.6%), and the difference between the 
two tested groups was statistically significant.
Most frequently, both buccal mucosas were in-
volved, being the only site of involvement in 58 
Australian patients (35.6%) and 66 Croatian patients 
(41.2%).
Involvement of other body surfaces
Skin involvement was found in 11.4% of cases in 
a study of Xue et al. (12). In our study, there were 15 
Australian patients with that presented with skin le-
sions (9.2%), and 3 patients with vulval lesions (1.8%). 
Furthermore, there were 17 Croatian patients with 
simultaneous skin lesions (10.6%) and only one with 
involvement of other mucosa (0.6%). 
Our results are not in concordance with Di Fede et 
al. (13), who reported that simultaneous vaginal/vul-
val lichen with OLP is seen in 75.6% patients. It seems 
that the prevalence was much lower in our patients. 
However, our patients did not undergo gynecologi-
cal examination routinely, and knowledge that they 
had vulval lesions was recorded by taking a detailed 
medical history.
CONCLUSION  
 None of the medical conditions which were inves-
tigated had significant correlation with OLP neither in 
Australian nor in Croatian patients with OLP. Further-
more, the use of drugs which metabolize through 
Cytochrome P450 (CYP450) was not significantly cor-
related with OLP in either studied population. There-
fore, we conclude that patients with OLP are not to be 
routinely screened for any systemic conditions.
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